Exposure to greater maternal maladaptive behaviors, such as cigarette smoking, may result in a greater vulnerability to other environmental risk factors, such as season of birth. This according to a recent study that applied linear regression analyses to examine season of birth as related to symptoms of attention deficit/hyperactivity disorder (ADHD) in early midlife. Researchers gathered longitudinal data on a prospective cohort of community-dwelling men and women (n=548) followed from adolescence to early midlife. They found:
- As compared with participants who were born in the summer, those who were born in the spring (Beta = 0.34; t-statistic = 3.59) had significantly more ADHD symptoms.
- In addition, exposure to maternal cigarette smoking in adolescence significantly intensified the association between season of birth and ADHD symptoms in early midlife.
Zhang C, Brook JS, Leukefeld CG, De La Rosa M, Brook DW. Season of birth: A predictor of ADHD symptoms in early midlife. [Published online ahead of print June 6, 2018]. Psychiatry Res. doi:10.1016/j.psychres.2018.05.056.
This Week's Must Reads
MMI a Valid Tool for Cognitive Training Intervention, Schizophr Res; ePub 2018 Dec 21; Hansen, et al
Targeted Auditory Training in Schizophrenia Assessed, Int J Psychophysiol; ePub 2018 Dec 29; Roach, et al
Brain Anomalies in FDRs of Those with Schizophrenia, Schizophr Bull; ePub 2018 Dec 28; de Zwarte, et al
Auditory Deficits in Persons with Schizophrenia, Schizophr Res; ePub 2019 Jan 18; Medalia, et al
Negative Symptom Domains in Schizophrenia and BD, Schizophr Bull; ePub 2019 Jan 14; Strauss, et al
Must Reads in ADHD
Nighttime Media Use in Adolescents with ADHD, Sleep Med; ePub 2018 Jul 28; Becker, Lienesch
Can Birth Season Predict ADHD in Early Midlife?, Psychiatry Res; ePub 2018 Jun 6; Zhang, et al
FDA Approves ADHD Drug for Patients 6 and Older, Neos Therapeutics news release; 2017 Sep 15
ADHD, CU Traits Markers for Conduct Problems, Psychiatry Res; ePub 2017 Sep 5; Babinski, et al
FDA Approves Cotempla XR-ODT for ADHD Patients 6-17, Neos Therapeutics, Inc. news release; 2017 Jun 19